PT - JOURNAL ARTICLE AU - L’Helgouach, Nicolas AU - Champigneux, Pierre AU - Schneider, Francisco Santos AU - Molina, Laurence AU - Espeut, Julien AU - Alali, Mellis AU - Baptiste, Julie AU - Cardeur, Lise AU - Dubuc, Benjamin AU - Foulongne, Vincent AU - Galtier, Florence AU - Makinson, Alain AU - Marin, Grégory AU - Picot, Marie-Christine AU - Prieux-Lejeune, Alexandra AU - Quenot, Marine AU - Robles, Francisco Checa AU - Salvetat, Nicolas AU - Vetter, Diana AU - Reynes, Jacques AU - Molina, Franck TI - EasyCOV : LAMP based rapid detection of SARS-CoV-2 in saliva AID - 10.1101/2020.05.30.20117291 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.30.20117291 4099 - http://medrxiv.org/content/early/2020/05/30/2020.05.30.20117291.short 4100 - http://medrxiv.org/content/early/2020/05/30/2020.05.30.20117291.full AB - Covid-19 crisis showed us that rapid massive virus detection campaign is a key element in SARS-CoV-2 pandemic response. The classical RT-PCR laboratory platforms must be complemented with rapid and simplified technologies to enhance efficiency of large testing strategies.To this aim, we developed EasyCOV, a direct saliva RT-LAMP based SARS-CoV-2 virus detection assay that do not requires any RNA extraction step. It allows robust and rapid response under safe and easy conditions for healthcare workers and patients.EasyCOV test was assessed under double blind clinical conditions (93 asymptomatic healthcare worker volonteers, 10 actively infected patients, 20 former infected patients tested during late control visit). EasyCOV results were compared with classical laboratory RT-PCR performed on nasopharyngeal samples.Our results show that compared with nasopharyngeal laboratory RT-PCR, EasyCOV SARS-CoV-2 detection test has a sensitivity of 72.7%. Measured on healthcare worker population the specificity was 95.7%. LAMP technology on saliva is clearly able to identify subjects with infectivity profile. Among healthcare worker population EasyCOV test detected one presymptomatic subject.Because it is simple, rapid and painless for patients, EasyCOV saliva SARS-Cov-2 detection test may be useful for large screening of general population.Competing Interest StatementThe authors declare that AP and FM have conflict of interest with SkillCell Company that develops the industrial version of the EasyCov Assay. The rest of authors have no conflict of interest identified.Clinical TrialNCT04337424Funding StatementThis work was financially supported by the CNRS, SkillCell, Region Occitanie and DGA (AID).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Reference of Clinical assay: NCT04337424 CPP Comity of Person Protection accepted under the registration number 20036-60435All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data from this study are available on demand.